Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial
Top Cited Papers
- 1 January 2003
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 361 (9353), 201-205
- https://doi.org/10.1016/s0140-6736(03)12268-4
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Successful treatment with recombinant factor VIIa of therapy‐resistant severe bleeding in a patient with acquired von Willebrand diseaseAmerican Journal of Hematology, 2001
- SUCCESSFUL USE OF RECOMBINANT FVIIa (NOVOSEVEN®) IN THE MANAGEMENT OF INTRACTABLE POST‐SURGICAL INTRA‐ABDOMINAL HAEMORRHAGEBritish Journal of Haematology, 1999
- Preoperative recombinant human erythropoietin injection versus preoperative autologous blood donation in patients undergoing radical retropubic prostatectomyUrology, 1997
- Autologous blood donation prior to anatomical radical retropublic prostatectomy: is it necessary?Urology, 1997
- The impact of pre‐donated autologous blood andBritish Journal of Urology, 1996
- Radical Retropubic Prostatectomy: Limited Benefit of Autologous Blood DonationJournal of Urology, 1995
- Intraoperative Blood Loss and Prognosis in Prostate Cancer Patients Undergoing Radical Retropubic ProstatectomyJournal of Urology, 1995
- The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor.Journal of Clinical Investigation, 1993
- The Risk of Transfusion-Transmitted InfectionNew England Journal of Medicine, 1992
- A randomized trial of perioperative hemodilution versus transfusion of preoperatively deposited autologous blood in elective surgeryTransfusion, 1992